William Blair Issues Pessimistic Forecast for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – William Blair dropped their Q1 2025 earnings estimates for LENZ Therapeutics in a report released on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now expects that the company will earn ($0.56) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($2.97) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.53) EPS.

Other analysts have also recently issued research reports about the stock. TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price target on the stock. Citigroup lifted their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Stock Performance

LENZ opened at $26.49 on Monday. The stock has a market capitalization of $728.50 million, a PE ratio of -5.55 and a beta of 0.58. The stock’s 50 day moving average price is $24.15 and its 200-day moving average price is $27.08. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Trading of LENZ Therapeutics

A number of hedge funds have recently modified their holdings of LENZ. Harbor Capital Advisors Inc. purchased a new position in LENZ Therapeutics during the 4th quarter valued at about $1,270,000. Parkman Healthcare Partners LLC bought a new position in shares of LENZ Therapeutics during the third quarter valued at approximately $3,308,000. Barclays PLC lifted its holdings in shares of LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after purchasing an additional 12,051 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of LENZ Therapeutics during the third quarter valued at approximately $743,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after purchasing an additional 81,901 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.